Figure 1.
PSMA and FDG screening. Patient presenting with enlarged liver metastases demonstrating low PSMA uptake on 68Ga-PSMA compared to normal liver and compared to FDG, leading to patient ineligibility for 177Lu-PSMA. Axial view of the (a) 68Ga-PSMA PET-CT and (b) the CT component. (c) Axial view of the 18 F-FDG PET-CT showing intense FDG uptake in the PSMA-negative areas of the lesion, ruling out the hypothesis of a purely necrotic origin for the absence of PSMA expression of the lesion.
